Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2025)

Historic Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $180.9 million.

  • Kiniksa Pharmaceuticals International's Revenue rose 6116.97% to $180.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.0 million, marking a year-over-year increase of 5568.24%. This contributed to the annual value of $423.2 million for FY2024, which is 5660.5% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Revenue is $180.9 million, which was up 6116.97% from $156.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Revenue ranged from a high of $180.9 million in Q3 2025 and a low of -$148.3 million during Q4 2022
  • For the 5-year period, Kiniksa Pharmaceuticals International's Revenue averaged around $67.6 million, with its median value being $75.7 million (2023).
  • Over the last 5 years, Kiniksa Pharmaceuticals International's Revenue had its largest YoY gain of 71963.62% in 2022, and its largest YoY loss of 89112.3% in 2022.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Revenue stood at $18.7 million in 2021, then tumbled by 891.12% to -$148.3 million in 2022, then skyrocketed by 156.24% to $83.4 million in 2023, then skyrocketed by 46.93% to $122.5 million in 2024, then surged by 47.59% to $180.9 million in 2025.
  • Its last three reported values are $180.9 million in Q3 2025, $156.8 million for Q2 2025, and $137.8 million during Q1 2025.